The clinical criteria were a CA-125 level ≥ 560 U/mL (OR 2.925, 95% CI 1.147–7.646) and a PNI ≤ 45.7 (OR 2.898, 95% CI 1.090–7.707), while the radiological criteria were site-specific tumor burden in the diaphragmatic surface of the spleen (OR 3.970, 95% CI 1.528–9.962), hepatorenal recess (OR 2.053, 95% CI 1.140–3.696), mesentery (OR 2.468, 95% CI 1.132–5.380) and upper abdominal total score (OR 1.278, 95% CI 1.149–1.421) (Table 2). The gene discussed is MUC16; the disease is neoplasm.